Can-Fite to raise $4M from warrant exercise
Can-Fite BioPharma Ltd. (CANF) entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 1,591,738 American Depositary Shares (ADSs).
Rhea-AI Filing Summary
Can-Fite BioPharma Ltd. (CANF) entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 1,591,738 American Depositary Shares (ADSs). The warrants, originally issued in March 2026 with an exercise price of $5.00 per ADS, will be exercised at a reduced price of $2.50 per ADS, under an effective Form F-3 registration statement. The transaction is expected to generate approximately $4.0 million in gross proceeds, with closing expected on or about September 3, 2026, subject to customary conditions.
In consideration for the cash exercise, Can-Fite will issue new unregistered warrants to purchase up to 3,183,476 ADSs at an exercise price of $2.50 per ADS, immediately exercisable until the twenty-four month anniversary of the effective date of a planned Resale Registration Statement. The company states it intends to use the net proceeds to fund research and development, clinical trials, and for other working capital and general corporate purposes.
Positive
- None.
Negative
- None.
Key Figures
Warrants exercised: 1,591,738 ADSs
Original exercise price: $5.00 per ADS
Reduced exercise price: $2.50 per ADS
+5 more
8 metrics
Warrants exercised
1,591,738 ADSs
Aggregate ADSs subject to outstanding warrants agreed to be immediately exercised
Original exercise price
$5.00 per ADS
Exercise price of warrants issued by Can-Fite in March 2026 before reduction
Reduced exercise price
$2.50 per ADS
New exercise price for the outstanding warrants being immediately exercised
Expected gross proceeds
$4.0 million
Gross proceeds expected from immediate exercise of the warrants before fees and expenses
New warrants issued
3,183,476 ADSs
ADSs underlying new unregistered warrants issued as consideration for cash exercise
New warrant exercise price
$2.50 per ADS
Exercise price of the new unregistered warrants
Resale registration period
24 months
New warrants exercisable until twenty-four month anniversary of effective date of Resale Registration Statement
Warrants ADS ratio
2.0 ADS per old warrant equivalent
New warrants to purchase 3,183,476 ADSs issued in exchange for exercise of warrants for 1,591,738 ADSs
Key Terms
American Depositary Shares, gross proceeds, private placement, Resale Registration Statement, +2 more
6 terms
gross proceeds financial
"exercise of Warrants for Approximately $4.0 Million in Gross Proceeds"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
private placement financial
"The new warrants described above were offered in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Resale Registration Statement regulatory
"until the twenty-four month anniversary of the effective date of the Resale Registration Statement"
A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.
Orphan Drug Designation medical
"Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation medical
"Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
FAQ
What capital raise did CANF announce in the September 2026 Form 6-K?
Can-Fite announced an agreement for the immediate exercise of certain outstanding warrants to purchase up to 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, generating expected gross proceeds of approximately $4.0 million, subject to customary closing conditions.
How many new warrants is Can-Fite BioPharma (CANF) issuing in this transaction?
In consideration for the cash exercise of existing warrants, Can-Fite will issue new unregistered warrants to purchase up to 3,183,476 ADSs. These new warrants have an exercise price of $2.50 per ADS and are immediately exercisable until the twenty-four month anniversary of the effective date of the Resale Registration Statement.
What are the exercise prices of the old and new CANF warrants?
The outstanding warrants being exercised were originally issued with an exercise price of $5.00 per ADS and will now be exercised at a reduced price of $2.50 per ADS. The new unregistered warrants issued as consideration also carry an exercise price of $2.50 per ADS.
How much cash does Can-Fite BioPharma (CANF) expect to receive from the warrant exercise?
Can-Fite expects gross proceeds of approximately $4.0 million from the immediate exercise of the outstanding warrants, before deducting placement agent fees and offering expenses, with H.C. Wainwright & Co. acting as the exclusive placement agent.
How will CANF use the proceeds from the warrant exercise?
Can-Fite states it intends to use the net proceeds from the approximately $4.0 million warrant exercise for funding research and development and clinical trials and for other working capital and general corporate purposes.
Are the new CANF warrants and underlying ADSs registered with the SEC?
The new warrants and the ADSs issuable upon their exercise are being offered in a private placement and have not been registered under the 1933 Act. Can-Fite has agreed to file a Resale Registration Statement with the SEC covering the resale of the ADSs issuable upon exercise of the new warrants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
